Although the anti-tumour response of CAR T cells is not within the natural MHC-II context of CD4+ T cells, it does clearly demonstrate the therapeutic potential of CD4+ CTLs as effector cells for anti-tumour immunotherapy. This evidence concerns the gene CD4 and neoplasm.